Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PCLX-001 |
| Synonyms | |
| Therapy Description |
PCLX-001 inhibits the N-myristoyl-transferases NMT1 and NMT2, potentially resulting in inhibition of early B-cell receptor signaling and degradation of pERK, c-Myc, NFkappaB and CREB, which may lead to tumor cell apoptosis, decreased cell proliferation, and inhibition of tumor growth (PMID: 33093447). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PCLX-001 | PCLX 001|PCLX001|Zelenirstat | PCLX-001 inhibits the N-myristoyl-transferases NMT1 and NMT2, potentially resulting in inhibition of early B-cell receptor signaling and degradation of pERK, c-Myc, NFkappaB and CREB, which may lead to tumor cell apoptosis, decreased cell proliferation, and inhibition of tumor growth (PMID: 33093447). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04836195 | Phase I | PCLX-001 | Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | Completed | CAN | 0 |
| NCT06613217 | Phase I | PCLX-001 | Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia | Recruiting | USA | 0 |